Clinical trial NCT01370655 (phase 1, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: mk-7145, hydrochlorothiazide (hctz), placebo to mk-7145, placebo to hctz
SMILES: CC1=C2COC(=O)C2=CC=C1[C@@H](O)CN1CCN(C[C@H](O)C2=C(C)C3=C(C=C2)C(=O)OC3)CC1, NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1, CC1=C2COC(=O)C2=CC=C1[C@@H](O)CN1CCN(C[C@H](O)C2=C(C)C3=C(C=C2)C(=O)OC3)CC1, NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
Eligibility criteria:

        Inclusion criteria:

          -  Diagnosis of essential hypertension

          -  Body mass index (BMI) ≤35 kg/m^2

          -  Participant in general good health

          -  No history of clinically significant arrhythmias or clinically significant abnormality
             on electrocardiogram (ECG)

          -  No history of clinically significant cardiac disease

          -  Treatment-naïve or taking up to 2 antihypertensive therapeutic agents

          -  Non-smoker and/or has not used nicotine or nicotine-containing products for at least 6
             months

        Exclusion criteria:

          -  Participant has low plasma potassium

          -  History of stroke, chronic seizures, or major neurological disorder

          -  History of clinically significant endocrine, gastrointestinal, cardiovascular,
             hematological, hepatic, immunological, renal, respiratory, or genitourinary
             abnormalities or diseases

          -  History of osteoporosis

          -  Active or history of nephrocalcinosis, nephrolithiasis or hypercalciuria

          -  Orthostatic change in vital sign measurements while going from a semi-recumbent to
             standing position accompanied by symptoms

          -  Functional disability that can interfere with rising from a semi-recumbent position to
             the standing position

          -  History of malignant neoplastic disease. Exceptions: (1) adequately treated
             non-melanomatous skin carcinoma; (2) other malignancies which have been successfully
             treated >10 years prior to the prestudy (screening) visit, (3) unlikely to sustain a
             recurrence

          -  Participant is unable to refrain from the use of prescription and non-prescription
             drugs such as high-dose aspirin (≥325 mg/day), strong/moderate Cytochrome P450 3A4
             (CYP3A4) inhibitors (such as ritonavir, indinavir, nelfinavir, erythromycin,
             telithromycin, clarithromycin, chloramphenicol, fluconazole, ketoconazole,
             itraconazole, nefazodone, aprepitant, verapamil, or diltiazem) as well as
             strong/moderate CYP3A4 inducers (such as phenytoin, carbamazepine, oxcarbazepine,
             phenobarbital, efavirenz, nevirapine, etravirine, rifampicin, modafinil, St Johns
             Wort, cyproterone, or progestin) beginning approximately 2 weeks (or 5 half-lives),
             prior to administration of the initial dose of study drug until the post study visit

          -  Current use of non-steroidal anti-inflammatory drugs (NSAIDs) other than low dose
             aspirin, aluminum- or magnesium-containing antacids, sucralfate, metal cations such as
             iron, multivitamins containing iron or zinc that cannot be discontinued at least 2
             weeks (or 5 half-lives) prior to administration of the initial dose of study drug
             until the post study visit

          -  Consumption of excessive amounts of alcohol, defined as greater than 3 glasses of
             alcoholic beverages (1 glass is approximately equivalent to: beer [284 mL/10 ounces],
             wine [125 mL/4 ounces], or distilled spirits [25 mL/1 ounce]) per day

          -  Participant consumes excessive amounts, defined as greater than 6 servings (1 serving
             is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, or other
             caffeinated beverages per day

          -  Major surgery, donation or lost 1 unit of blood (approximately 500 mL), or
             participation in another investigational study within 4 weeks prior to the prestudy
             (screening)

          -  History of significant multiple and/or severe allergies (including latex allergy), or
             has had an anaphylactic reaction or significant intolerability to prescription or
             non-prescription drugs or food

          -  Regular use of any illicit drugs or history of drug abuse within approximately 6
             months

          -  Dehydration or volume-depletion